

Risk Minimisation Measures

Virtual Live Training Course

27-29 October 2026 | 13:00-17:30 CEST



Overview

The proactive planning of risk minimisation measures (RMMs) in the context of optimizing the benefit-risk profiles of medicinal product is a challenging task. RMMs should be commensurate to the risk in relation to the clinical benefit of the product and should work for the intended patient population without adding undue burden on the healthcare systems.

After the recent updates to GVP XVI, it's clear that they should also allow for rapid evaluation of their effectiveness to enable evidence-based adaptation to achieve their objectives or align to a changing healthcare environment, if and when necessary.

In this course, we will share experiences and challenges in designing, implementing, and evaluating RMMs in different regulatory settings and different therapeutic areas, as well as presenting an outlook on what may be the next generation of RMM tools.

Learning Objectives

At the conclusion of this virtual live training course, participants will be able to:

- Design a risk management strategy
- Select the appropriate tools for risk minimisation
- Choose the right measures to evaluate effectiveness

Who Will Attend

This intermediate level virtual live training course is intended for professionals working within the pharmaceutical industry in pharmacovigilance, drug safety, risk management and regulatory affairs.

Ideally, participants should have experience in risk management.

Key Topics

- Introduction and overview of changes to risk management
- Regulatory framework for risk management
- Designing global risk management strategy
- Tools for risk minimisation
- Implementation of risk minimisation measures
- Measuring effectiveness
- Risk minimisation measures findings from an assessor's perspective
- Evolving landscape and future outlook

Faculty

Omar Aimer

President of the ISoP North American Chapter
ISoP, Canada

Mark Perrott

Managing Partner
Axian Consulting, United Kingdom

Anita Volkers

Pharmacovigilance Assessor
Medicines Evaluation Board, Netherlands

Schedule-At-A-Glance

DAY 1

13:00 WELCOME AND INTRODUCTION OF FACULTY AND PARTICIPANTS, INTRODUCTION TO GROUP WORK

13:45 SESSION 1

INTRODUCTION AND OVERVIEW OF CHANGES TO RISK MANAGEMENT

Anita Volkers

- Risks classifying for inclusion RMP (evolvement)
- New challenges in risk management

14:15 SESSION 2

REGULATORY FRAMEWORK FOR RISK MANAGEMENT

Anita Volkers and Omar Aimer

- Updates in GVP Module XVI Rev 3
- Different country/region requirements in the EU, UK, US and brief overview of other regions
- Harmonisation initiatives

15:45 BREAK

16:15 SESSION 3

DESIGNING GLOBAL RISK MANAGEMENT STRATEGY

Mark Perrott and Anita Volkers

- Aligning risk management strategy and structured benefit-risk assessment
- Defining strategic goals of risk minimisation
- Prioritising risks and defining risk management objectives
- Requested (features of) aRMM (regulator view)

17:30 END OF DAY 1

16:00 BREAK

16:30 SESSION 6

MEASURING EFFECTIVENESS

Mark Perrott and Anita Volkers

- The effectiveness measurement challenge
- Do the FDA and EMA approaches conflict or align
- Aligning risk management objectives with measures of effectiveness
- What are the regulatory expectations at submission and beyond

17:30 END OF DAY 2

DAY 3

13:00 SESSION 6 CONT.

MEASURING EFFECTIVENESS

Anita Volkers and Mark Perrott

- PASS Studies
- Potential for digital tools to provide new approaches
- Specific interventions and their measurement, e.g. Valproate

13:30 SESSION 7

RISK MINIMISATION MEASURES FINDINGS FROM ASSESSOR'S PERSPECTIVE

Anita Volkers

- Digital access/dissemination
- RM control tools
- Barriers and enablers of effectiveness (qualitative data)

14:30 BREAK

15:00 SESSION 8

EVOLVING LANDSCAPE AND FUTURE OUTLOOK

Anita Volkers, Omar Aimer and Mark Perrott

- Future trends in RMM implementation
- Common implementation barriers
- Future digital approaches / platforms for risk management and implications
- Open forum for participant insights and experiences

16:00 SESSION 9

GROUP WORK PART 2

17:00 Q&A

17:30 END OF VIRTUAL LIVE TRAINING COURSE

Unless otherwise disclosed, DIA acknowledges that the statements made by speakers are their own opinion and not necessarily that of the organisation they represent, or that of the DIA. Speakers and agenda are subject to change without notice. Recording during DIA sessions is strictly prohibited without prior written consent from DIA.



Group Discounts

Register 3 individuals from the same company for the same course and receive complimentary registration for a 4th!*

To take advantage of this offer, please print the registration form for EACH of the four registrants from your company. Include the names of all four group registrants on each of the forms and return them together via email to basel@diaglobal.org.

**Terms and Conditions apply. Please contact DIA EMEA office for more information.*



Customized Professional Development for Your Team

Get a customized training for your department (or even across different departments!) and benefit from increased:

- Knowledge of a topic of your choice
- Flexibility & Convenience
- Cost Effectiveness

Or explore [eLearning](#) to allow self-paced learning.

For more information please contact basel@diaglobal.org



About DIA

DIA is the global connector in the life sciences product development process. Our association of more than 18,000 members builds productive relationships by bringing together regulators, innovators, and influencers to exchange knowledge and collaborate in an impartial setting. DIA's network creates unparalleled opportunities for exchange of knowledge and has the inter-disciplinary experience to prepare for future developments.

The dedicated efforts of DIA staff, members and speakers enable DIA to provide a comprehensive catalogue of conferences, workshops, training courses, scientific publications and educational materials. DIA is a global community representing thousands of stakeholders working together to bring safe and effective products to patients.

DIA is an independent, non-profit organisation has its Global Center in Washington, DC, USA with the European office in Basel, Switzerland, and additional regional offices in Horsham, Pennsylvania, USA; Tokyo, Japan; Mumbai, India; and Beijing, China.



Technical Requirements

To test your system compatibility, please click on the link: <https://diaglobal.zoom.us/test>

For further information on system requirements, please visit the website:
<https://www.diaglobal.org/General/System-Requirements>



Continuing Education

All DIA training courses have been awarded a PharmaTrain Centre Recognition.

PharmaTrain Federation is a not for profit organisation that started its activities as an IMI (Innovative Medicines Initiative) European Project. Its mission is to drive implementation of globally recognized high-level standards for postgraduate education and training in Medicines Development. To that aim, the Federation is assessing Continuous Professional Development (CPD) Courses and Course Providers around the world that deserve recognition.



REGISTRATION FORM

RMMs Virtual Live Training Course # 26550
27-29 October 2026 | 13:00-17:30 CEST



REGISTRATION FEES

Registration fee includes full admission to virtual course, electronic access to training course materials. **Please note that the full amount must be received by DIA by commencement of the course to get the electronic access to the material.** Please check:

FEES	MEMBER EARLY-BIRD valid until 29 Sep 2026	MEMBER valid from 30 Sep 2026	NON- MEMBER
INDUSTRY/ REPRESENTATIVE	€ 1'215.00 <input type="checkbox"/>	€ 1'350.00 <input type="checkbox"/>	€ 1'610.00 <input type="checkbox"/>
ACADEMIA/CHARITABLE/GOVERNMENT/NON-PROFIT (FULL-TIME)	NA	€ 675.00 <input type="checkbox"/>	€ 935.00 <input type="checkbox"/>

A special discount for SMEs on the standard fee is available for a limited number of places. To prove your status as an SME, a confirmation of the European Medicines Agency is necessary. Please contact DIA for more information.

All registration fees are subject to VAT if applicable.

Please enter your company's VAT number: _____

If DIA cannot verify your membership upon receipt of registration form, you will be charged the non-member fee.

DIA MEMBERSHIP

All nonmember fees include a one year DIA membership, at no additional cost. Explore membership benefits at [DIAGlobal.org/Membership](https://diaglobal.org/Membership).

DIA membership will renew automatically at the end of the complimentary membership term, at the then current membership rates. You may cancel automatic membership renewal at any time by accessing your account online at [DIAGlobal.org](https://diaglobal.org). If you would like to decline complimentary membership, please indicate your preference below.

I would like to decline a one year complimentary DIA membership.

The DIA Contact Centre Team will be pleased to assist you with your registration from Monday to Friday between 09:00 and 17:00 CE(S)T. **Tel.** :+41 61 225 51 51

Email: Basel@DIAGlobal.org **Mail:** DIA, Küchengasse 16, 4051 Basel, Switzerland

Web: www.DIAglobal.org

ATTENDEE DETAILS

Please complete in block capital letters or attach the attendee's business card here.

Prof Dr Ms Mr

Last Name

First Name

Job Title

Company

Address

Postal Code

City

Country

Telephone Number

Attendee email required for course material access

PAYMENT METHOD

DIA accepts only Credit Card as a payment method.

Payments by VISA, Mastercard or AMEX are accepted. Other types of credit card are not accepted.

You will receive a payment link in the coming days to complete the payment.

Please complete payment within 7 days of receipt of the payment link.

Payments will be net of all charges and bank charges will be borne by the payer.

If you have not received your confirmation within five working days, please contact basel@diaglobal.org.

By signing below, I confirm that I read and agree with DIA's Terms and Conditions of booking.

These are available from the office or online by clicking:

[http://www.diaglobal.org/EUterms](https://www.diaglobal.org/EUterms)

Date	Signature
------	-----------